Literature DB >> 10327354

[Thiotepa eyedrops for prevention of pterygium recurrence: 18 years of use].

A Tassy1, D Ribe.   

Abstract

PURPOSE: To analyze effectiveness and side effects of thiotepa eyedrops utilized to prevent postoperative pterygium recurrence, with a retrospective study allowing a long follow-up.
METHODS: This work deals with 64 cases of pterygium, among them 8 were recurrent. Only growing or very important pterygiums were operated on (14 cases were reaching the pupillary area). Surgical techniques were simple ones (almost always excision with simple conjunctival closure or translation of conjunctival flaps, no corneal grafts). Following surgery, patients received thiotepa eyedrops (dilution: 1/2000), four times a day, during 6 to 8 weeks.
RESULTS: Tolerance of treatment was good on the whole, and there was no important complications. There were only 2 cases of recurrence (3%).
CONCLUSION: Thiotepa was effective and allowed us to avoid using complex surgical techniques to prevent recurrence (especially corneal grafts), even in recurrent pterygiums or pterygiums reaching the pupillary area.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10327354

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  3 in total

1.  Inhibitory effect of PPARγ agonist on the proliferation of human pterygium fibroblasts.

Authors:  Yuan Zou; Mingchang Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

Review 2.  Developments and current approaches in the treatment of pterygium.

Authors:  Dilek Hacıoğlu; Hidayet Erdöl
Journal:  Int Ophthalmol       Date:  2016-09-23       Impact factor: 2.031

Review 3.  Pterygium: an update on pathophysiology, clinical features, and management.

Authors:  Toktam Shahraki; Amir Arabi; Sepehr Feizi
Journal:  Ther Adv Ophthalmol       Date:  2021-05-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.